

Vladimir Dăvâk

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5268301/publications.pdf>

Version: 2024-02-01

205
papers

17,712
citations

26630

56
h-index

13379

130
g-index

221
all docs

221
docs citations

221
times ranked

12326
citing authors

#	ARTICLE	IF	CITATIONS
1	Early Revascularization in Acute Myocardial Infarction Complicated by Cardiogenic Shock. New England Journal of Medicine, 1999, 341, 625-634.	27.0	2,596
2	Therapeutic Anticoagulation with Heparin in Noncritically Ill Patients with Covid-19. New England Journal of Medicine, 2021, 385, 790-802.	27.0	778
3	Therapeutic Anticoagulation with Heparin in Critically Ill Patients with Covid-19. New England Journal of Medicine, 2021, 385, 777-789.	27.0	712
4	Effects of Ramipril and Vitamin E on Atherosclerosis. Circulation, 2001, 103, 919-925.	1.6	698
5	Ticagrelor with or without Aspirin in High-Risk Patients after PCI. New England Journal of Medicine, 2019, 381, 2032-2042.	27.0	683
6	A Prospective, Randomized Clinical Trial of Hemodynamic Support With Impella 2.5 Versus Intra-Aortic Balloon Pump in Patients Undergoing High-Risk Percutaneous Coronary Intervention. Circulation, 2012, 126, 1717-1727.	1.6	680
7	Coronary Intervention for Persistent Occlusion after Myocardial Infarction. New England Journal of Medicine, 2006, 355, 2395-2407.	27.0	635
8	Cardiogenic shock complicating acute myocardial infarction—etiologies, management and outcome: a report from the SHOCK Trial Registry. Journal of the American College of Cardiology, 2000, 36, 1063-1070.	2.8	622
9	Early Revascularization and Long-term Survival in Cardiogenic Shock Complicating Acute Myocardial Infarction. JAMA - Journal of the American Medical Association, 2006, 295, 2511.	7.4	572
10	Randomized Trial of Primary PCI with or without Routine Manual Thrombectomy. New England Journal of Medicine, 2015, 372, 1389-1398.	27.0	536
11	Routine Early Angioplasty after Fibrinolysis for Acute Myocardial Infarction. New England Journal of Medicine, 2009, 360, 2705-2718.	27.0	483
12	Inotropes and Vasopressors. Circulation, 2008, 118, 1047-1056.	1.6	391
13	Effects of Radial Versus Femoral Artery Access in Patients With Acute Coronary Syndromes With or Without ST-Segment Elevation. Journal of the American College of Cardiology, 2012, 60, 2490-2499.	2.8	349
14	Outcome and profile of ventricular septal rupture with cardiogenic shock after myocardial infarction: a report from the SHOCK Trial Registry. Journal of the American College of Cardiology, 2000, 36, 1110-1116.	2.8	329
15	Effect of Tilarginine Acetate in Patients With Acute Myocardial Infarction and Cardiogenic Shock. JAMA - Journal of the American Medical Association, 2007, 297, 1657.	7.4	327
16	Impact of thrombolysis, intra-aortic balloon pump counterpulsation, and their combination in cardiogenic shock complicating acute myocardial infarction: a report from the SHOCK Trial Registry. Journal of the American College of Cardiology, 2000, 36, 1123-1129.	2.8	303
17	Long-Term Effects of Cholesterol Lowering and Angiotensin-Converting Enzyme Inhibition on Coronary Atherosclerosis. Circulation, 2000, 102, 1748-1754.	1.6	260
18	Classification of coronary artery bifurcation lesions and treatments: Time for a consensus!. Catheterization and Cardiovascular Interventions, 2008, 71, 175-183.	1.7	260

#	ARTICLE	IF	CITATIONS
19	Primary Stenting Versus Balloon Angioplasty in Occluded Coronary Arteries. <i>Circulation</i> , 1999, 100, 236-242.	1.6	251
20	Thrombus Aspiration in ST-Segmentâ€Elevation Myocardial Infarction. <i>Circulation</i> , 2017, 135, 143-152.	1.6	233
21	Outcomes after thrombus aspiration for ST elevation myocardial infarction: 1-year follow-up of the prospective randomised TOTAL trial. <i>Lancet</i> , The, 2016, 387, 127-135.	13.7	187
22	Cardiogenic shock due to cardiac free-wall rupture or tamponade after acute myocardial infarction: a report from the SHOCK Trial Registry. <i>Journal of the American College of Cardiology</i> , 2000, 36, 1117-1122.	2.8	168
23	Echocardiographic Predictors of Survival and Response to Early Revascularization in Cardiogenic Shock. <i>Circulation</i> , 2003, 107, 279-284.	1.6	153
24	Radial Artery Patency After Transradial Catheterization. <i>Circulation: Cardiovascular Interventions</i> , 2012, 5, 127-133.	3.9	153
25	Predictors of long-term outcome after crush stenting of coronary bifurcation lesions: Importance of the bifurcation angle. <i>American Heart Journal</i> , 2006, 152, 762-769.	2.7	146
26	Randomized Trial of Percutaneous Coronary Intervention for Subacute Infarct-Related Coronary Artery Occlusion to Achieve Long-Term Patency and Improve Ventricular Function. <i>Circulation</i> , 2006, 114, 2449-2457.	1.6	139
27	Multiple Infections and Subsequent Cardiovascular Events in the Heart Outcomes Prevention Evaluation (HOPE) Study. <i>Circulation</i> , 2003, 107, 251-257.	1.6	136
28	A severity scoring system for risk assessment of patients with cardiogenic shock: A report from the SHOCK Trial and Registry. <i>American Heart Journal</i> , 2010, 160, 443-450.	2.7	127
29	Long-term survival in 11,661 patients with multivessel coronary artery disease in the era of stenting: A report from the Alberta Provincial Project for Outcome Assessment in Coronary Heart Disease (APPROACH) Investigators. <i>American Heart Journal</i> , 2001, 142, 119-126.	2.7	124
30	Sex Differences in Access to Coronary Revascularization after Cardiac Catheterization: Importance of Detailed Clinical Data. <i>Annals of Internal Medicine</i> , 2002, 136, 723.	3.9	118
31	Effect of Radial Versus Femoral Access on Radiation Dose and the Importance of Procedural Volume. <i>JACC: Cardiovascular Interventions</i> , 2013, 6, 258-266.	2.9	117
32	Regulation of Human ApoA-I by Gemfibrozil and Fenofibrate Through Selective Peroxisome Proliferator-Activated Receptor Î± Modulation. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2005, 25, 585-591.	2.4	116
33	Functional Status and Quality of Life After Emergency Revascularization for Cardiogenic Shock Complicating Acute Myocardial Infarction. <i>Journal of the American College of Cardiology</i> , 2005, 46, 266-273.	2.8	113
34	Absence of gender differences in clinical outcomes in patients with cardiogenic shock complicating acute myocardial infarction. <i>Journal of the American College of Cardiology</i> , 2001, 38, 1395-1401.	2.8	106
35	N-acetylcysteine reduces contrast-associated nephropathy but not clinical events during long-term follow-up. <i>American Heart Journal</i> , 2004, 148, 690-695.	2.7	104
36	Decreased complication rates using the transradial compared to the transfemoral approach in percutaneous coronary intervention in the era of routine stenting and glycoprotein platelet IIb/IIIa inhibitor use: A large single-center experience. <i>American Heart Journal</i> , 2008, 156, 864-870.	2.7	104

#	ARTICLE	IF	CITATIONS
37	Predictors of 30-day mortality in patients with refractory cardiogenic shock following acute myocardial infarction despite a patent infarct artery. American Heart Journal, 2009, 158, 680-687.	2.7	98
38	Effects of late percutaneous transluminal coronary angioplasty of an occluded infarct-related coronary artery on left ventricular function in patients with a recent (<6 weeks) Q-wave acute myocardial infarction (total occlusion post-myocardial infarction intervention study [TOMIIS]). American Heart Journal, 2009, 158, 680-687.	1.6	96
39	Stroke in the TOTAL trial: a randomized trial of routine thrombectomy vs. percutaneous coronary intervention alone in ST elevation myocardial infarction. European Heart Journal, 2015, 36, 2364-2372.	2.2	95
40	Effect of nitric oxide synthase inhibition on haemodynamics and outcome of patients with persistent cardiogenic shock complicating acute myocardial infarction: a phase II dose-ranging study. European Heart Journal, 2007, 28, 1109-1116.	2.2	93
41	Ticagrelor alone vs. ticagrelor plus aspirin following percutaneous coronary intervention in patients with non-ST-segment elevation acute coronary syndromes: TWILIGHT-ACS. European Heart Journal, 2020, 41, 3533-3545.	2.2	93
42	Timing of Staged Nonculprit Artery Revascularization in Patients With ST-Segment Elevation Myocardial Infarction. Journal of the American College of Cardiology, 2019, 74, 2713-2723.	2.8	88
43	Effect of Vasopressin on Hemodynamics in Patients With Refractory Cardiogenic Shock Complicating Acute Myocardial Infarction. American Journal of Cardiology, 2005, 96, 1617-1620.	1.6	86
44	Impact of renal insufficiency on outcome after contemporary percutaneous coronary intervention. American Heart Journal, 2006, 151, 146-152.	2.7	85
45	Metabolic Profiling of Arginine and Nitric Oxide Pathways Predicts Hemodynamic Abnormalities and Mortality in Patients With Cardiogenic Shock After Acute Myocardial Infarction. Circulation, 2007, 116, 2315-2324.	1.6	85
46	Clinical and Angiographic Outcomes With Sirolimus-Eluting Stents in Total Coronary Occlusions. JACC: Cardiovascular Interventions, 2009, 2, 97-106.	2.9	73
47	The Absorb Bioresorbable Vascular Scaffold in Coronary Bifurcations. JACC: Cardiovascular Interventions, 2014, 7, 81-88.	2.9	70
48	Role of transesophageal echocardiography in the diagnosis and management of prosthetic valve thrombosis. Journal of the American College of Cardiology, 1991, 18, 1829-1833.	2.8	69
49	First Experience With Direct Factor Xa Inhibition in Patients With Stable Coronary Disease. Circulation, 2002, 105, 2385-2391.	1.6	69
50	Thrombus Aspiration in Patients With High Thrombus Burden in the TOTAL Trial. Journal of the American College of Cardiology, 2018, 72, 1589-1596.	2.8	67
51	Design and rationale of the TOTAL trial: A randomized trial of routine aspiration Thrombectomy with percutaneous coronary intervention (PCI) versus PCI Alone in patients with ST-elevation myocardial infarction undergoing primary PCI. American Heart Journal, 2014, 167, 315-321.e1.	2.7	66
52	Predictors of improvement in left ventricular function after percutaneous revascularization of occluded coronary arteries: A report from the Total Occlusion Study of Canada (TOSCA). American Heart Journal, 2001, 142, 301-308.	2.7	65
53	Outcome of patients aged ≥75 years in the Should we emergently revascularize Occluded Coronaries in cardiogenic shock (SHOCK) trial: Do elderly patients with acute myocardial infarction complicated by cardiogenic shock respond differently to emergent revascularization?. American Heart Journal, 2005, 149, 1128-1134.	2.7	65
54	Pseudoaneurysm after transradial cardiac catheterization: Case series and review of the literature. Catheterization and Cardiovascular Interventions, 2012, 80, 283-287.	1.7	60

#	ARTICLE	IF	CITATIONS
55	Culprit lesion thrombus burden after manual thrombectomy or percutaneous coronary intervention-alone in ST-segment elevation myocardial infarction: the optical coherence tomography sub-study of the TOTAL (Thrombectomy versus PCI Alone) trial. <i>European Heart Journal</i> , 2015, 36, 1892-1900.	2.2	60
56	A 16-week fenofibrate treatment increases LDL particle size in type IIA dyslipidemic patients. <i>Atherosclerosis</i> , 2002, 162, 363-371.	0.8	59
57	The late open artery hypothesis—A decade later. <i>American Heart Journal</i> , 2001, 142, 411-421.	2.7	57
58	Predictors of Radial Artery Size in Patients Undergoing Cardiac Catheterization: Insights From the Good Radial Artery Size Prediction (GRASP) Study. <i>Canadian Journal of Cardiology</i> , 2014, 30, 211-216.	1.7	57
59	European Bifurcation Club white paper on stenting techniques for patients with bifurcated coronary artery lesions. <i>Catheterization and Cardiovascular Interventions</i> , 2020, 96, 1067-1079.	1.7	57
60	Design and methodology of the Occluded Artery Trial (OAT). <i>American Heart Journal</i> , 2005, 150, 627-642.	2.7	56
61	The SPIRIT V Study. <i>JACC: Cardiovascular Interventions</i> , 2011, 4, 168-175.	2.9	55
62	The Adverse Long-Term Impact of Renal Impairment in Patients Undergoing Percutaneous Coronary Intervention in the Drug-Eluting Stent Era. <i>Circulation: Cardiovascular Interventions</i> , 2009, 2, 309-316.	3.9	53
63	The Toronto score for in-hospital mortality after percutaneous coronary interventions. <i>American Heart Journal</i> , 2009, 157, 156-163.	2.7	53
64	Impact of Renal Insufficiency on Angiographic, Procedural, and In-Hospital Outcomes Following Percutaneous Coronary Intervention. <i>American Journal of Cardiology</i> , 2008, 101, 780-785.	1.6	51
65	Thrombocytopenia at baseline is a predictor of inhospital mortality in patients undergoing percutaneous coronary intervention. <i>American Heart Journal</i> , 2008, 156, 120-124.	2.7	51
66	Systemic Inflammatory Response Syndrome Is Associated With Increased Mortality Across the Spectrum of Shock Severity in Cardiac Intensive Care Patients. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2020, 13, e006956.	2.2	51
67	Study of Cardiovascular Risk Intervention by Pharmacists (SCRIP): A Randomized Trial Design of the Effect of a Community Pharmacist Intervention Program on Serum Cholesterol Risk. <i>Annals of Pharmacotherapy</i> , 1999, 33, 910-919.	1.9	50
68	Stent Thrombosis and Bleeding Complications After Implantation of Sirolimus-Eluting Coronary Stents in an Unselected Worldwide Population. <i>Journal of the American College of Cardiology</i> , 2011, 57, 1445-1454.	2.8	50
69	Long-Term Outcomes After Percutaneous Coronary Intervention of Bifurcation Narrowings. <i>American Journal of Cardiology</i> , 2008, 102, 404-410.	1.6	48
70	Radial versus femoral access for elderly patients with acute coronary syndrome undergoing coronary angiography and intervention: insights from the RIVAL trial. <i>American Heart Journal</i> , 2015, 170, 880-886.	2.7	46
71	Increased circulating monocyte activation in patients with unstable coronary syndromes. <i>Journal of the American College of Cardiology</i> , 2001, 38, 1340-1347.	2.8	45
72	The ability to achieve complete revascularization is associated with improved in-hospital survival in cardiogenic shock due to myocardial infarction: Manitoba cardiogenic shock registry investigators. <i>Catheterization and Cardiovascular Interventions</i> , 2011, 78, 540-548.	1.7	45

#	ARTICLE	IF	CITATIONS
73	Severe hemolysis associated with use of the impella LP 2.5 mechanical assist device. Catheterization and Cardiovascular Interventions, 2012, 80, 840-844.	1.7	45
74	Clinical Outcomes of Treatment by Percutaneous Coronary Intervention Versus Coronary Artery Bypass Graft Surgery in Patients With Chronic Kidney Disease Undergoing Index Revascularization in Ontario. Circulation: Cardiovascular Interventions, 2015, 8, .	3.9	42
75	Tolerability of statin-fibrate and statin-niacin combination therapy in dyslipidemic patients at high risk for cardiovascular events. American Journal of Cardiology, 2002, 89, 390-394.	1.6	40
76	Rationale and design of the Trial of Routine ANgioplasty and Stenting After Fibrinolysis to Enhance Reperfusion in Acute Myocardial Infarction (TRANSFER-AMI). American Heart Journal, 2008, 155, 19-25.	2.7	40
77	Optimizing rotational atherectomy in high-risk percutaneous coronary interventions: Insights from the PROTECT IT™ study. Catheterization and Cardiovascular Interventions, 2014, 83, 1057-1064.	1.7	40
78	Balloon crush: Treatment of bifurcation lesions using the crush stenting technique as adapted for transradial approach of percutaneous coronary intervention. Catheterization and Cardiovascular Interventions, 2004, 63, 412-416.	1.7	39
79	Reinfarction after percutaneous coronary intervention or medical management using the universal definition in patients with total occlusion after myocardial infarction: Results from long-term follow-up of the Occluded Artery Trial (OAT) cohort. American Heart Journal, 2012, 163, 563-571.	2.7	36
80	Myocardial blush and microvascular reperfusion following manual thrombectomy during percutaneous coronary intervention for ST elevation myocardial infarction: insights from the TOTAL trial. European Heart Journal, 2016, 37, 1891-1898.	2.2	36
81	Impact of Left Ventricular Ejection Fraction on Clinical Outcomes Over Five Years After Infarct-Related Coronary Artery Recanalization (from the Occluded Artery Trial [OAT]). American Journal of Cardiology, 2010, 105, 10-16.	1.6	35
82	Cardiometabolic effects of rosiglitazone in patients with type 2 diabetes and coronary artery bypass grafts: A randomized placebo-controlled clinical trial. Atherosclerosis, 2010, 211, 565-573.	0.8	34
83	Long-Term Effects of Percutaneous Coronary Intervention of the Totally Occluded Infarct-Related Artery in the Subacute Phase After Myocardial Infarction. Circulation, 2011, 124, 2320-2328.	1.6	34
84	Relationship between risk stratification at admission and treatment effects of early invasive management following fibrinolysis: insights from the Trial of Routine ANgioplasty and Stenting After Fibrinolysis to Enhance Reperfusion in Acute Myocardial Infarction (TRANSFER-AMI). European Heart Journal, 2011, 32, 1994-2002.	2.2	34
85	Impact of delays to cardiac surgery after failed angioplasty and stenting. Journal of the American College of Cardiology, 2004, 43, 337-342.	2.8	33
86	Hemodynamic Parameters Are Prognostically Important in Cardiogenic Shock But Similar Following Early Revascularization or Initial Medical Stabilization. Chest, 2007, 132, 1794-1803.	0.8	33
87	Sex Differences in the Management and Outcomes of Ontario Patients With Cardiogenic Shock Complicating Acute Myocardial Infarction. Canadian Journal of Cardiology, 2013, 29, 691-696.	1.7	31
88	Antithrombotic Therapy After Coronary Stenting in Patients With Nonvalvular Atrial Fibrillation. Canadian Journal of Cardiology, 2013, 29, 213-218.	1.7	28
89	The sPLA ₂ Inhibition to Decrease Enzyme Release After Percutaneous Coronary Intervention (SPIDER-PCI) Trial. Circulation, 2010, 122, 2411-2418.	1.6	27
90	Clinical impact of direct stenting and interaction with thrombus aspiration in patients with ST-segment elevation myocardial infarction undergoing percutaneous coronary intervention: Thrombectomy Trialists Collaboration. European Heart Journal, 2018, 39, 2472-2479.	2.2	27

#	ARTICLE	IF	CITATIONS
91	A modified balloon crush approach improves side branch access and side branch stent apposition during crush stenting of coronary bifurcation lesions. Catheterization and Cardiovascular Interventions, 2006, 68, 365-371.	1.7	26
92	Health-related quality of life outcomes of patients with coronary artery disease treated with cardiac surgery, percutaneous coronary intervention or medical management. Canadian Journal of Cardiology, 2004, 20, 1259-66.	1.7	26
93	Prediction of Distal Embolization During Percutaneous Coronary Intervention in Saphenous Vein Grafts. American Journal of Cardiology, 2007, 99, 603-606.	1.6	25
94	Incidence and Outcomes Associated With Early Heart Failure Pharmacotherapy in Patients With Ongoing Cardiogenic Shock. Critical Care Medicine, 2014, 42, 281-288.	0.9	25
95	Outcomes Among Clopidogrel, Prasugrel, and Ticagrelor in ST-Elevation Myocardial Infarction Patients Who Underwent Primary Percutaneous Coronary Intervention From the TOTAL Trial. Canadian Journal of Cardiology, 2019, 35, 1377-1385.	1.7	24
96	The Presence of a CTO in a Non-Infarct-Related Artery During a STEMI Treated With Contemporary Primary PCI Is Associated With Increased Rates of Early and Late Cardiovascular Morbidity and Mortality. JACC: Cardiovascular Interventions, 2018, 11, 709-711.	2.9	23
97	Regular Drug-Eluting Stent vs Dedicated Coronary Bifurcation BioSS Expert Stent: Multicenter Open-Label Randomized Controlled POLBOS I Trial. Canadian Journal of Cardiology, 2015, 31, 671-678.	1.7	22
98	Triple wire technique for removal of fractured angioplasty guidewire. Journal of Invasive Cardiology, 2007, 19, E230-4.	0.4	22
99	Electrophysiological Effects of Late Percutaneous Coronary Intervention for Infarct-Related Coronary Artery Occlusion. Circulation, 2009, 119, 779-787.	1.6	21
100	Evaluation of a New Heparin Agent in Percutaneous Coronary Intervention. Circulation, 2010, 121, 1713-1721.	1.6	21
101	Temporal Trends in Cardiogenic Shock Treatment and Outcomes Among Ontario Patients With Myocardial Infarction Between 1992 and 2008. Circulation: Cardiovascular Quality and Outcomes, 2011, 4, 440-447.	2.2	21
102	Spontaneous dissection of the left main coronary artery. Canadian Journal of Cardiology, 2004, 20, 815-8.	1.7	21
103	Rapid complete reversal of systemic hypoperfusion after intra-aortic balloon pump counterpulsation and survival in cardiogenic shock complicating an acute myocardial infarction. American Heart Journal, 2011, 162, 268-275.	2.7	19
104	Transfer for urgent percutaneous coronary intervention early after thrombolysis for ST-elevation myocardial infarction: The TRANSFER-AMI pilot feasibility study. Canadian Journal of Cardiology, 2006, 22, 1121-1126.	1.7	18
105	In-hospital outcomes of very elderly patients (85 years and older) undergoing percutaneous coronary intervention. Catheterization and Cardiovascular Interventions, 2011, 77, 634-641.	1.7	18
106	The Canadian Association of Interventional Cardiology and the Canadian Cardiovascular Society joint statement on drug-eluting stents. Canadian Journal of Cardiology, 2007, 23, 121-123.	1.7	17
107	Long-term outcomes using a two-stent technique for the treatment of coronary bifurcations. International Journal of Cardiology, 2013, 168, 446-451.	1.7	17
108	A multicentre, randomized, double-blind placebo-controlled trial evaluating rosiglitazone for the prevention of atherosclerosis progression after coronary artery bypass graft surgery in patients with type 2 diabetes. Design and rationale of the Veln-Coronary aTherOsclerosis and Rosiglitazone after bypass surgery (VICTORY) trial. Canadian Journal of Cardiology, 2009, 25, 509-515.	1.7	16

#	ARTICLE	IF	CITATIONS
109	Medical Therapy v. PCI in Stable Coronary Artery Disease. Medical Decision Making, 2013, 33, 891-905.	2.4	16
110	Efficacy and Safety of the GuideLiner Motherâ€¢inâ€¢Child Guide Catheter Extension in Percutaneous Coronary Intervention. Journal of Interventional Cardiology, 2017, 30, 46-55.	1.2	15
111	Long-Term Safety and Effectiveness of Drug-Eluting Stents for the Treatment of Saphenous Vein Grafts Disease. JACC: Cardiovascular Interventions, 2011, 4, 965-973.	2.9	14
112	Association Between Drug-Eluting Stent Type and Clinical Outcomes in Patients With Chronic Kidney Disease Undergoing Percutaneous Coronary Intervention. Canadian Journal of Cardiology, 2014, 30, 1170-1176.	1.7	14
113	Effect of serum lipid concentrations on restenosis after successful de novo percutaneous transluminal coronary angioplasty in patients with total cholesterol 160 to 240 mg/dl and triglycerides <350 mg/dl. American Journal of Cardiology, 1995, 75, 936-938.	1.6	13
114	Quantitative coronary angiography findings of patients who received previous breast radiotherapy. Radiotherapy and Oncology, 2011, 100, 184-188.	0.6	13
115	Rotational atherectomy through the radial artery is associated with similar procedural success when compared with the transfemoral route. Coronary Artery Disease, 2015, 26, 254-258.	0.7	13
116	Complex bifurcation percutaneous coronary intervention with the Absorb bioresorbable vascular scaffold. EuroIntervention, 2013, 9, 888-888.	3.2	13
117	Preoperative Intraaortic Balloon Pump Improves Early Outcomes Following High-Risk Coronary Artery Bypass Graft Surgery: A Meta-Analysis of Randomized Trials and Prospective Study Design. Journal of Invasive Cardiology, 2018, 30, 2-9.	0.4	13
118	Percutaneous coronary intervention in the Occluded Artery Trial: Procedural success, hazard, and outcomes over 5 years. American Heart Journal, 2009, 158, 408-415.	2.7	12
119	Late outcomes following percutaneous coronary interventions: Results from a large, observational registry. Canadian Journal of Cardiology, 2010, 26, e218-e224.	1.7	12
120	The Sirolimus-Eluting Cypher Select Coronary Stent for the Treatment of Bare-Metal and Drug-Eluting Stent Restenosis. JACC: Cardiovascular Interventions, 2012, 5, 64-71.	2.9	12
121	Twoâ€¢year outcomes after deployment of XIENCE V everolimusâ€¢eluting stents in patients undergoing percutaneous coronary intervention of bifurcation lesions: A report from the SPIRIT V single arm study. Catheterization and Cardiovascular Interventions, 2013, 82, E163-72.	1.7	12
122	An international survey of clinical practice during primary percutaneous coronary intervention for ST-elevation myocardial infarction with a focus on aspiration thrombectomy. EuroIntervention, 2013, 8, 1143-1148.	3.2	12
123	Prevention and Regression of Coronary Atherosclerosis. Chest, 1994, 105, 718-726.	0.8	11
124	Effects of half ironman competition on the development of late potentials. Medicine and Science in Sports and Exercise, 2000, 32, 1208-1213.	0.4	10
125	Sirolimus-Eluting Coronary Stents in Octogenarians. JACC: Cardiovascular Interventions, 2011, 4, 982-991.	2.9	10
126	Percutaneous revascularization and long term clinical outcomes of diabetic patients randomized in the Occluded Artery Trial (OAT). International Journal of Cardiology, 2013, 168, 2416-2422.	1.7	10

#	ARTICLE	IF	CITATIONS
127	Long-term Follow-up of the Trial of Routine Angioplasty and Stenting After Fibrinolysis to Enhance Reperfusion in Acute Myocardial Infarction (TRANSFER-AMI). Canadian Journal of Cardiology, 2018, 34, 736-743.	1.7	10
128	New frontiers and unresolved controversies in percutaneous coronary intervention. American Journal of Cardiology, 2003, 91, 27-33.	1.6	9
129	Selective use of embolic protection devices during saphenous vein grafts interventions: A single-center experience. Catheterization and Cardiovascular Interventions, 2010, 75, 1037-1044.	1.7	9
130	Myocardial Perfusion Grade After Late Infarct Artery Recanalization Is Associated With Global and Regional Left Ventricular Function at One Year. Circulation: Cardiovascular Interventions, 2010, 3, 549-555.	3.9	9
131	Meta-Analysis of Intensive Lipid-Lowering Therapy in Patients With Polyvascular Disease. Journal of the American Heart Association, 2021, 10, e017948.	3.7	9
132	A calcified neointima-"stent" within a stent. Journal of Invasive Cardiology, 2009, 21, 141-3.	0.4	9
133	Prognostic significance of diabetes as a predictor of survival after cardiac catheterization. American Journal of Medicine, 2000, 109, 543-548.	1.5	8
134	Angiographic and clinical outcomes of drug-eluting versus bare metal stent deployment in the Occluded Artery Trial. Catheterization and Cardiovascular Interventions, 2009, 73, 771-779.	1.7	8
135	Efficacy of early invasive management post-fibrinolysis in men versus women with ST-elevation myocardial infarction: A subgroup analysis from Trial of Routine Angioplasty and Stenting after Fibrinolysis to Enhance Reperfusion in Acute Myocardial Infarction (TRANSFER-AMI). American Heart Journal, 2012, 164, 343-350.	2.7	7
136	One-Year Outcome of Small-Vessel Disease Treated with Sirolimus-Eluting Stents: A Subgroup Analysis of the eSELECT Registry. Journal of Interventional Cardiology, 2013, 26, 163-172.	1.2	7
137	Efficacy of Early Invasive Management After Fibrinolysis for ST-Segment Elevation Myocardial Infarction in Relation to Initial Troponin Status. Canadian Journal of Cardiology, 2016, 32, 1221.e11-1221.e18.	1.7	7
138	Coronary Revascularization in Patients With Advanced Chronic Kidney Disease. Canadian Journal of Cardiology, 2019, 35, 1002-1014.	1.7	7
139	Does ticlopidine reduce reocclusion and other adverse events after successful balloon angioplasty of occluded coronary arteries? Results from the Total Occlusion Study of Canada (TOSCA). American Heart Journal, 2001, 142, 776-781.	2.7	6
140	Long-term Outcome of Unprotected Left Main Stenting: A Canadian Tertiary Care Experience. Canadian Journal of Cardiology, 2014, 30, 1407-1414.	1.7	6
141	Reperfusion Times for Radial Versus Femoral Access in Patients With ST-Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention. Circulation: Cardiovascular Interventions, 2015, 8, .	3.9	6
142	Primary PCI with or without Thrombectomy. New England Journal of Medicine, 2015, 373, 680-683.	27.0	6
143	Response by Jolly et al to Letters Regarding Article, "Thrombus Aspiration in ST-Segment-Elevation Myocardial Infarction: An Individual Patient Meta-Analysis: Thrombectomy Trialists Collaboration". Circulation, 2017, 135, e1103-e1104.	1.6	6
144	Ticagrelor Monotherapy After PCI in High-Risk Patients With Prior MI. JACC: Cardiovascular Interventions, 2022, 15, 282-293.	2.9	6

#	ARTICLE	IF	CITATIONS
145	Effects of long term cholesterol lowering on coronary atherosclerosis in patient risk factor subgroups: the Simvastatin/enalapril Coronary Atherosclerosis Trial (SCAT). Canadian Journal of Cardiology, 2003, 19, 487-91.	1.7	6
146	Percutaneous Treatment of Dissection of the Ascending Aorta Occurring as a Complication During Coronary Angioplasty of a Saphenous Vein Bypass Graft. Journal of Interventional Cardiology, 2005, 18, 45-48.	1.2	5
147	Distribution and determinants of myocardial perfusion grade following late mechanical recanalization of occluded infarct-related arteries postmyocardial infarction: A report from the occluded artery trial. Catheterization and Cardiovascular Interventions, 2008, 72, 783-789.	1.7	5
148	First Canadian experience with high-risk percutaneous coronary intervention with assistance of a percutaneously deployed left ventricular assist device. Canadian Journal of Cardiology, 2008, 24, e82-e85.	1.7	5
149	Long-term Outcomes After Percutaneous Intervention of the Internal Thoracic Artery Anastomosis: The Use of Drug-Eluting Stents Is Associated With a Higher Need of Repeat Revascularization. Canadian Journal of Cardiology, 2012, 28, 458-463.	1.7	5
150	Efficacy of an Early Invasive Strategy After Fibrinolysis in ST-Elevation Myocardial Infarction Relative to the Extent of Coronary Artery Disease. Canadian Journal of Cardiology, 2014, 30, 1555-1561.	1.7	5
151	Characteristics and outcomes of patients undergoing percutaneous coronary intervention within 1 year of coronary artery bypass graft surgery. Catheterization and Cardiovascular Interventions, 2017, 90, 186-193.	1.7	5
152	Coronary intervention for chronic total occlusion. Coronary Artery Disease, 2017, 28, 426-436.	0.7	5
153	Upstream anticoagulation for patients with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention: Insights from the TOTAL trial. Catheterization and Cardiovascular Interventions, 2020, 96, 519-525.	1.7	5
154	Routine use of glycoprotein IIb/IIIa inhibitor therapy is associated with an improved in-hospital outcome after percutaneous coronary intervention: Insights from a large, prospective, single-centre registry. Canadian Journal of Cardiology, 2005, 21, 27-32.	1.7	5
155	Long-term outcomes after a strategy of percutaneous coronary intervention of the infarct-related artery with drug-eluting stents or bare metal stents vs medical therapy alone in the Occluded Artery Trial (OAT). American Heart Journal, 2012, 163, 1011-1018.	2.7	4
156	Choice of stent and outcomes after treatment of drug-eluting stent restenosis in highly complex lesions. Catheterization and Cardiovascular Interventions, 2013, 81, E16-22.	1.7	4
157	Risks of Overinterpreting Interim Data. Circulation, 2018, 137, 206-209.	1.6	4
158	Association of Thrombus Aspiration With Time and Mortality Among Patients With ST-Segment Elevation Myocardial Infarction. JAMA Network Open, 2021, 4, e213505.	5.9	4
159	The prognostic significance of grade of ischemia in the ECG in patients with ST-elevation myocardial infarction: A substudy of the randomized trial of primary PCI with or without routine manual thrombectomy (TOTAL trial). Journal of Electrocardiology, 2021, 68, 65-71.	0.9	4
160	Variations in Coronary Revascularization Practices and Their Effect on Long-Term Outcomes. Journal of the American Heart Association, 2022, 11, e022770.	3.7	4
161	Prognostic Role of Residual Thrombus Burden Following Thrombectomy: Insights From the TOTAL Trial. Circulation: Cardiovascular Interventions, 2022, 15, e011336.	3.9	4
162	Late Potentials in Female Triathletes Before and After Prolonged Strenuous Exercise. Applied Physiology, Nutrition, and Metabolism, 2003, 28, 153-164.	1.7	3

#	ARTICLE	IF	CITATIONS
163	A Meta-Analysis That Misses the Mark. Journal of the American College of Cardiology, 2008, 52, 578-580.	2.8	3
164	Inhibition of sPLA2 and Endothelial Function: A Substudy of the SPIDER-PCI Trial. Canadian Journal of Cardiology, 2012, 28, 215-221.	1.7	3
165	Decreased risk of stent fractureâ€related restenosis between paclitaxelâ€eluting stents and sirolimus eluting stents: Results of longâ€term followâ€up. Catheterization and Cardiovascular Interventions, 2012, 79, 559-565.	1.7	3
166	Proximal Optimization Technique and Kissing Balloon Inflations With the Bioresorbable Vascular Scaffold for Coronary Bifurcation Percutaneous Coronary Intervention. Canadian Journal of Cardiology, 2014, 30, 1461.e5-1461.e7.	1.7	3
167	Efficacy and Safety of a Routine Early Invasive Strategy in Relation to Time from Symptom Onset to Fibrinolysis (a Subgroup Analysis of TRANSFER-AMI). American Journal of Cardiology, 2015, 115, 1005-1012.	1.6	3
168	Kawasaki disease and coronary intervention: A word of caution. International Journal of Cardiology, 2015, 201, 646-647.	1.7	3
169	Oneâ€year clinical outcomes after sirolimusâ€eluting coronary stent implantation in diabetics enrolled in the worldwide eâ€scp>SELECT</scp> registry. Catheterization and Cardiovascular Interventions, 2016, 87, 52-62.	1.7	3
170	INCIDENCE AND PREDICTORS OF NO REFLOW PHENOMENON: INSIGHTS FROM THE TOTAL TRIAL. Journal of the American College of Cardiology, 2017, 69, 1179.	2.8	3
171	Bare metal versus drug eluting stents for ST-segment elevation myocardial infarction in the TOTAL trial. International Journal of Cardiology, 2017, 248, 120-123.	1.7	3
172	Oral inflammatory load in patients with coronary artery disease. Journal of Oral Science, 2019, 61, 412-417.	1.7	3
173	Unloading Is Not the Only Question in Cardiogenic Shock. Journal of the American College of Cardiology, 2019, 73, 663-666.	2.8	3
174	The high-risk ECG pattern of ST-elevation myocardial infarction: A substudy of the randomized trial of primary PCI with or without routine manual thrombectomy (TOTAL trial). International Journal of Cardiology, 2020, 319, 40-45.	1.7	3
175	Antiplatelet Therapy in Patients Undergoing Elective Percutaneous Coronary Intervention. Current Cardiology Reports, 2022, 24, 277-293.	2.9	3
176	Effect of bare metal stenting on angiographic and clinical outcomes in diabetic and nondiabetic patients undergoing percutaneous coronary intervention of nonacute occluded coronary arteries: A report from the total occlusion study of Canada (TOSCA). Catheterization and Cardiovascular Interventions, 2005, 66, 178-184.	1.7	2
177	The use of lipid-lowering therapy for secondary prevention in patients undergoing percutaneous coronary intervention. Canadian Journal of Cardiology, 2006, 22, 419-423.	1.7	2
178	Effect of Late Revascularization of a Totally Occluded Coronary Artery After Myocardial Infarction on Mortality Rates in Patients With Renal Impairment. American Journal of Cardiology, 2012, 110, 954-960.	1.6	2
179	Oneâ€Year Clinical Outcomes after Sirolimusâ€Eluting Coronary Stent Implantation for Acute Myocardial Infarction in the Worldwide eâ€SELECT Registry. Journal of Interventional Cardiology, 2012, 25, 253-261.	1.2	2
180	Comparison of Late Results of Percutaneous Coronary Intervention Among Stable Patients â‰65 Versus >65 Years of Age With an Occluded Infarct Related Artery (from the Occluded Artery Trial). American Journal of Cardiology, 2012, 109, 614-619.	1.6	2

#	ARTICLE	IF	CITATIONS
181	Routine Intra-Aortic Balloon Pump Support in High-Risk Cardiac Surgery Patients. Critical Care Medicine, 2013, 41, 2642-2644.	0.9	2
182	Complex coronary artery bifurcation treatment utilizing everolimus-eluting bioresorbable vascular scaffolds and optical coherence tomography. Coronary Artery Disease, 2014, 25, 629-631.	0.7	2
183	Effects of timing, location and definition of reinfarction on mortality in patients with totally occluded infarct related arteries late after myocardial infarction. International Journal of Cardiology, 2014, 174, 90-95.	1.7	2
184	Biodegradable Stent Platforms: Are We Heading in the Right Direction?. Canadian Journal of Cardiology, 2015, 31, 957-959.	1.7	2
185	Inadvertent detachment of an entrapped Cutting Balloon from the balloon catheter during treatment of in-stent restenosis. Journal of Invasive Cardiology, 2005, 17, E27-9.	0.4	2
186	Bifurcating saphenous vein and left internal thoracic graft anatomy: Treatment of a left main equivalent saphenous interposition vein graft lesion and virtual histology/grey scale IVUS characterization post-intervention. International Journal of Cardiology, 2007, 122, 179-181.	1.7	1
187	Loss of short-term symptomatic benefit in patients with an occluded infarct artery is unrelated to non-protocol revascularization: Results from the Occluded Artery Trial (OAT). American Heart Journal, 2011, 161, 84-90.	2.7	1
188	Drug eluting stent implantation in patients requiring concomitant vitamin K antagonist therapy. One-year outcome of the worldwide e-SELECT registry. International Journal of Cardiology, 2013, 168, 2522-2527.	1.7	1
189	Role of Optical Coherence Tomography in the Assessment of Stent Deformation. Canadian Journal of Cardiology, 2016, 32, 396.e1-396.e2.	1.7	1
190	Recurrent MI and stroke post-acute coronary syndrome: Which is the lesser evil?. American Heart Journal, 2017, 187, 191-193.	2.7	1
191	The Association of Atrial Fibrillation before Percutaneous Coronary Intervention with 1-Year Outcome in ST-elevation Myocardial Infarction patients. CJC Open, 2021, 3, 1221-1229.	1.5	1
192	Double-blind, placebo-controlled evaluation of bioresorbable liposomal alendronate in diabetic patients undergoing PCI: The BLADE-PCI trial. American Heart Journal, 2022, 249, 45-56.	2.7	1
193	Multivessel Intervention in ST-Segment Elevation Myocardial Infarction: Evidence-Based Practice or Guesswork?. Circulation: Cardiovascular Interventions, 2021, 14, e011015.	3.9	1
194	Late Intervention on an Occluded Infarct-Related Artery: A Meta-analysis of the Randomized Controlled Trials. Clinical Medicine Cardiology, 2007, 1, CMC.S356.	0.1	0
195	Response to Letter Regarding Article, "Metabolic Profiling of Arginine and Nitric Oxide Pathways Predicts Hemodynamic Abnormalities and Mortality in Patients With Cardiogenic Shock After Acute Myocardial Infarction". Circulation, 2008, 118, .	1.6	0
196	General Management: Pharmacotherapy and Mechanical Ventilation. , 0, , 45-77.		0
197	Cardiogenic Shock Without Flow-Limiting Angiographic Coronary Artery Disease (from the Should) Tj ETQq1 1 0.784314 rgBT /Overl American Journal of Cardiology, 2009, 104, 24-28.	1.6	0
198	N-terminal-pro-B-type natriuretic peptide in cardiogenic shock: A marker ready for prime time or a therapeutic target?*. Critical Care Medicine, 2009, 37, 2091-2092.	0.9	0

#	ARTICLE	IF	CITATIONS
199	Percutaneous coronary intervention of a circumflex artery chronic total occlusion using the retrograde approach via ipsilateral collateral circulation from the left anterior descending artery. <i>Cor Et Vasa</i> , 2012, 54, e209-e212.	0.1	0
200	Bioresorbable Vascular Scaffolds: A New Revolution in Percutaneous Coronary Intervention?. <i>Canadian Journal of Cardiology</i> , 2015, 31, 247-249.	1.7	0
201	Stenting of the proximal left anterior descending and restenosis. <i>Coronary Artery Disease</i> , 2016, 27, 439-441.	0.7	0
202	Adjunctive Bare-Metal Stenting Associated With Improved Outcomes in Patients With Multivessel Disease Treated With Drug-Eluting Stents. <i>Canadian Journal of Cardiology</i> , 2016, 32, 1231-1238.	1.7	0
203	ONE-YEAR OUTCOME OF ACUTE STENT THROMBOSIS: INSIGHTS FROM THE TOTAL TRIAL. <i>Journal of the American College of Cardiology</i> , 2017, 69, 1181.	2.8	0
204	A detailed analysis of patients included in the Summary Hospital-level Mortality Indicator (SHMI) for myocardial infarction (MI) – all is not what it seems?. <i>BMJ Open Quality</i> , 2020, 9, e000836.	1.1	0
205	Restenosis and Reocclusion after Recanalization of an Occluded Coronary Artery: Is There a Light at the End of This Tunnel?. <i>Current Interventional Cardiology Reports</i> , 2001, 3, 311-320.	0.4	0